[Molecular-targeted therapy for prostate cancer]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Context:

• Hormone-refractory prostate cancer has limited effective treatments.
• Molecular targeted therapies are under investigation.
• Nuclear factor kappa B (NFkappaB) plays a crucial role in prostate cancer progression.

Purpose:

• To explore NFkappaB as a therapeutic target in prostate cancer.
• To evaluate the efficacy of NFkappaB inhibitors, including dexamethasone.

Summary:

• NFkappaB is a critical target for prostate cancer therapy.
• Bortezomib and thalidomide showed limited efficacy alone but some benefit with chemotherapy.
• Dexamethasone inhibits NFkappaB and interleukin-6, offering potential benefits beyond androgen blockade, including anemia improvement.

Impact:

• Dexamethasone's multifaceted mechanism offers a new therapeutic avenue for hormone-refractory prostate cancer.
• Targeting NFkappaB and related pathways may overcome treatment resistance.
• Potential to improve patient outcomes, including anemia, in advanced prostate cancer settings.